Follow
Yet another study showing that tumor mutation burden is a poor predictor of response to checkpoint blockade.
"First we assembled the largest pan-cancer dataset of immunotherapy patients with sequencing and clinical data. Surprisingly, we find little evidence that TMB is predictive of response to ICB.
(...)
Our analysis shows that the use of TMB in clinical practice is not supported by available data and can deprive patients of treatment to which they are likely to respond."
#Immunology #immunooncology #immunotherapy
